

Angelo Avogaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2958486/publications.pdf>

Version: 2024-02-01

360
papers

19,894
citations

10389

72
h-index

15266

126
g-index

376
all docs

376
docs citations

376
times ranked

21820
citing authors

#	ARTICLE	IF	CITATIONS
1	Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 115-124.	3.3	12
2	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <sc>ITAS</sc> post hoc analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 327-331.	4.4	2
3	Hematopoietic and Nonhematopoietic <i>p66Shc</i> Differentially Regulates Stem Cell Traffic and Vascular Response to Ischemia in Diabetes. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 593-607.	5.4	6
4	Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 177-186.	4.4	11
5	A novel MRPS34 gene mutation with combined OXPHOS deficiency in an adult patient with Leigh syndrome. <i>Molecular Genetics and Metabolism Reports</i> , 2022, 30, 100830.	1.1	1
6	Effectiveness of remote screening for diabetic retinopathy among patients referred to Mozambican Diabetes Association (AMODIA): a retrospective observational study. <i>Acta Diabetologica</i> , 2022, 59, 563.	2.5	1
7	Anthropometrics, Dietary Intake and Body Composition in Urea Cycle Disorders and Branched Chain Organic Acidemias: A Case Study of 18 Adults on Low-Protein Diets. <i>Nutrients</i> , 2022, 14, 467.	4.1	2
8	Response to Chia Siang Kow and colleagues. <i>Acta Diabetologica</i> , 2022, 59, 287.	2.5	0
9	Hyperglycemia, Reduced Hematopoietic Stem Cells, and Outcome of COVID-19. <i>Diabetes</i> , 2022, 71, 788-794.	0.6	8
10	Glycemic control after switching to faster aspart in adults with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1181-1188.	3.3	3
11	In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study. <i>Scientific Reports</i> , 2022, 12, 3474.	3.3	8
12	The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and meta-analysis. <i>International Journal of Cardiology</i> , 2022, 357, 123-127.	1.7	2
13	EMG analysis across different tasks improves prevention screenings in diabetes: a cluster analysis approach. <i>Medical and Biological Engineering and Computing</i> , 2022, 60, 1659.	2.8	1
14	Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care. <i>Acta Diabetologica</i> , 2022, 59, 921-928.	2.5	4
15	Performance assessment across different care settings of a heart failure hospitalisation risk-score for type 2 diabetes using administrative claims. <i>Scientific Reports</i> , 2022, 12, 7762.	3.3	1
16	Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 221, 106873.	4.7	3
17	A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease. <i>Diabetologia</i> , 2022, 65, 1555-1568.	6.3	5
18	Assessment of simple strategies for identifying undiagnosed diabetes and prediabetes in the general population. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 75-81.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Effects of glucose variability on hematopoietic stem/progenitor cells in patients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 119-126.	3.3	8
20	Comparative effectiveness of dapagliflozin vs <scp>DPP</scp>â€4 inhibitors on a composite endpoint of <scp>HbA1c</scp>, body weight and blood pressure reduction in the real world. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3353.	4.0	17
21	Incidence of heart failure in patients with type 1 diabetes: a systematic review of observational studies. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 745-753.	3.3	9
22	Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 419-427.	2.0	31
23	Comparing the accuracy of transcutaneous sensor and 90-day implantable glucose sensor. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 650-657.	2.6	7
24	SARS CoV2 infection in a young subject affected by arginosuccinate synthase deficiency: A case report of epilepsy worsening. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 26, 100698.	1.1	2
25	The Toll of Lockdown Against COVID-19 on Diabetes Outpatient Care: Analysis From an Outbreak Area in Northeast Italy. <i>Diabetes Care</i> , 2021, 44, e18-e21.	8.6	31
26	Efficacy of telemedicine for persons with type 1 diabetes during Covid19 lockdown. <i>Nutrition and Diabetes</i> , 2021, 11, 1.	3.2	30
27	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1879-1889.	3.3	24
28	Recurrent Neural Network to Predict Renal Function Impairment in Diabetic Patients via Longitudinal Routine Check-up Data. <i>Lecture Notes in Computer Science</i> , 2021, , 329-337.	1.3	0
29	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. <i>Acta Diabetologica</i> , 2021, 58, 789-796.	2.5	0
30	SGLT-2âinhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. <i>Cardiovascular Diabetology</i> , 2021, 20, 39.	6.8	35
31	The â€œEarly Treatmentâ€Approach Reducing Cardiovascular Risk in Patients with Typeâ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. <i>Diabetes Therapy</i> , 2021, 12, 1445-1461.	2.5	5
32	Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care. <i>Diabetes Research and Clinical Practice</i> , 2021, 173, 108686.	2.8	6
33	Where diabetes care meets cardiovascular research: our cardiovascular perspective at a Centre devoted to diabetes research and care. <i>European Heart Journal</i> , 2021, 42, 2417-2419.	2.2	0
34	Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 217-240.	5.7	19
35	Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1288.	2.4	10
36	Inhibition of SGLT2 Rescues Bone Marrow Cell Traffic for Vascular Repair: Role of Glucose Control and Ketogenesis. <i>Diabetes</i> , 2021, 70, 1767-1779.	0.6	17

#	ARTICLE	IF	CITATIONS
37	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 453-464.	1.9	2
38	SGLT2 inhibitors: Do we need other evidences?. European Journal of Internal Medicine, 2021, 87, 18-19.	2.2	0
39	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	6.8	3
40	A simple way to spotlight hidden heart failure in type 2 diabetes?. European Journal of Heart Failure, 2021, 23, 1094-1096.	7.1	1
41	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	2.6	5
42	Managing diabetes in diabetic patients with COVID: where do we start from?. Acta Diabetologica, 2021, 58, 1441-1450.	2.5	5
43	High prolactin levels in dihydropteridine reductase deficiency: A sign of therapy failure or additional pathology?. JIMD Reports, 2021, 61, 48-51.	1.5	4
44	Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targetsâ€™ attainment in subjects with and without type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 144.	6.8	17
45	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	2.6	7
46	Fenofibrate increases circulating haematopoietic stem cells in people with diabetic retinopathy: a randomised, placebo-controlled trial. Diabetologia, 2021, 64, 2334-2344.	6.3	9
47	Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies. Diabetes Research and Clinical Practice, 2021, 179, 109024.	2.8	6
48	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3474-3483.	2.6	7
49	Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. Journal of Endocrinological Investigation, 2021, 44, 1379-1386.	3.3	35
50	Why diabetes outpatient clinics should not close during pandemic crises. Journal of Endocrinological Investigation, 2021, 44, 1795-1798.	3.3	1
51	Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. European Journal of Preventive Cardiology, 2021, 28, 22-29.	1.8	12
52	Effects of the chymase inhibitor fulacimstat in diabetic kidney diseaseâ€™ results from the CADA DIA trial. Nephrology Dialysis Transplantation, 2021, 36, 2263-2273.	0.7	12
53	Coronary perivascular inflammation in type 2 diabetes mellitus patients: the missing piece in the puzzle of their increased cardiovascular risk?. European Heart Journal, 2021, 42, .	2.2	0
54	105.3: Analysis of Autoimmune Re-activation After COVID-19 mRNA Vaccination in Pancreas Transplant Recipients. Transplantation, 2021, 105, S2-S2.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study. <i>Cardiovascular Diabetology</i> , 2021, 20, 222.	6.8	7
56	Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 329-336.	3.3	9
57	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
58	Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. <i>Acta Diabetologica</i> , 2020, 57, 367-375.	2.5	20
59	Diabetes diagnosis from administrative claims and estimation of the true prevalence of diabetes among 4.2 million individuals of the Veneto region (North East Italy). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 84-91.	2.6	33
60	Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming. <i>Diabetes Care</i> , 2020, 43, 501-507.	8.6	36
61	Estradiol correlates with erectile dysfunction and its severity in type 2 diabetic patients. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107728.	2.3	2
62	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2629-2635.	3.8	71
63	Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 4221-4234.	2.4	13
64	Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. <i>Cardiovascular Diabetology</i> , 2020, 19, 190.	6.8	22
65	Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1925-1934.	4.4	14
66	Performance of the Steno type 1 risk engine for cardiovascular disease prediction in Italian patients with type 1 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1813-1819.	2.6	15
67	Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study. <i>Diabetes Therapy</i> , 2020, 11, 2629-2645.	2.5	14
68	Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. <i>Diabetes Research and Clinical Practice</i> , 2020, 168, 108374.	2.8	147
69	Pharmacologic PPAR- γ Activation Reprograms Bone Marrow Macrophages and Partially Rescues HSPC Mobilization in Human and Murine Diabetes. <i>Diabetes</i> , 2020, 69, 1562-1572.	0.6	18
70	Cardiovascular and heart failure outcomes with type 2 diabetes therapies: how important is weight loss?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 353-355.	11.4	4
71	Euglycemic Ketoacidosis. <i>Current Diabetes Reports</i> , 2020, 20, 25.	4.2	19
72	Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. <i>Diabetes Therapy</i> , 2020, 11, 1369-1379.	2.5	150

#	ARTICLE	IF	CITATIONS
73	Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double-blind, placebo-controlled trial. <i>Stem Cells Translational Medicine</i> , 2020, 9, 965-973.	3.3	13
74	Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1946-1950.	4.4	91
75	Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. <i>Cardiovascular Diabetology</i> , 2020, 19, 74.	6.8	26
76	Diabetic retinopathy: looking beyond the eyes. <i>Diabetologia</i> , 2020, 63, 1662-1664.	6.3	11
77	Prevalence and impact of diabetes among people infected with SARS-CoV-2. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 867-869.	3.3	371
78	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001451.	2.8	48
79	Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. <i>Metabolism: Clinical and Experimental</i> , 2020, 106, 154190.	3.4	20
80	Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2020, 36, e3304.	4.0	11
81	Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 817-827.	4.4	19
82	<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 161-174.	2.4	105
83	High-protein diet: A barrier to the nephroprotective effects of sodium-glucose co-transporter-2 inhibitors?. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1511-1515.	4.4	4
84	Diabetes mellitus impairs circulating proangiogenic granulocytes. <i>Diabetologia</i> , 2020, 63, 1872-1884.	6.3	13
85	Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2617-e2625.	3.6	17
86	Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2464-2474.	3.6	7
87	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2020, , 131-159.	0.1	0
88	Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 345-349.	3.3	11
89	Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 252-260.	4.4	33
90	Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 106.	6.8	21

#	ARTICLE	IF	CITATIONS
91	Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2542-2552.	4.4	19
92	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
93	One-year caloric restriction and 12-week exercise training intervention in obese adults with type 2 diabetes: emphasis on metabolic control and resting metabolic rate. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1497-1507.	3.3	5
94	Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. <i>Journal of the American Heart Association</i> , 2019, 8, e012244.	3.7	8
95	Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4966.	4.1	21
96	Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5431-5444.	3.6	64
97	Improved long-term cardiovascular outcomes after intensive versus standard screening of diabetic complications: an observational study. <i>Cardiovascular Diabetology</i> , 2019, 18, 117.	6.8	11
98	Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. <i>Acta Diabetologica</i> , 2019, 56, 1051-1060.	2.5	10
99	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 399-414.	2.0	26
100	Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1886-1894.	4.4	17
101	Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 1099-1107.	3.3	13
102	Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway. <i>Diabetes</i> , 2019, 68, 1303-1314.	0.6	47
103	Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 496-503.	2.6	7
104	Ultrasound Tissue Characterization of Carotid Plaques Differs Between Patients with Type 1 Diabetes and Subjects without Diabetes. <i>Journal of Clinical Medicine</i> , 2019, 8, 424.	2.4	8
105	The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 421-431.	2.6	52
106	Microvascular complications in diabetes: A growing concern for cardiologists. <i>International Journal of Cardiology</i> , 2019, 291, 29-35.	1.7	93
107	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000725.	2.8	26
108	Comparative effectiveness of exenatide once-weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta-analysis of observational studies. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1255-1260.	4.4	10

#	ARTICLE	IF	CITATIONS
109	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. <i>Acta Diabetologica</i> , 2019, 56, 605-617.	2.5	50
110	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2019, , 1-29.	0.1	0
111	Diabetic retinopathy: a tool for cardiovascular risk stratification. <i>Diabetes Mellitus</i> , 2019, 22, 455-460.	1.9	0
112	Insulin treatment in patients with diabetes and heart failure: defendant on the stand. <i>European Journal of Heart Failure</i> , 2018, 20, 896-897.	7.1	2
113	Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1781-1786.	4.4	32
114	The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1686-1695.	2.4	23
115	The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. <i>Acta Diabetologica</i> , 2018, 55, 593-601.	2.5	103
116	Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000475.	2.8	26
117	Head-to-head comparison of the accuracy of Abbott FreeStyle Libre and Dexcom G5 mobile. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 425-427.	2.6	42
118	Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1367-1368.	4.4	5
119	FreeStyle Libre and Dexcom G4 Platinum sensors: Accuracy comparisons during two weeks of home use and use during experimentally induced glucose excursions. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 180-186.	2.6	50
120	Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. <i>Diabetes and Metabolism</i> , 2018, 44, 333-340.	2.9	5
121	Keeping the right track in the treatment of patients with type 2 diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 52-54.	7.1	2
122	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2981.	4.0	23
123	Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1048-1055.	3.6	8
124	Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. <i>Diabetes Therapy</i> , 2018, 9, 851-861.	2.5	14
125	Sodium-glucose cotransporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 25-33.	4.4	76
126	Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose cotransporter-2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 740-744.	4.4	31

#	ARTICLE	IF	CITATIONS
127	Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2018, 9, 27-36.	2.5	5
128	Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3773-3782.	3.6	29
129	Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. <i>Acta Diabetologica</i> , 2018, 55, 1121-1129.	2.5	2
130	Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2018, 142, 63-73.	2.8	42
131	Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. <i>Diabetes Therapy</i> , 2018, 9, 1477-1490.	2.5	12
132	Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance. <i>FASEB Journal</i> , 2018, 32, 4004-4015.	0.5	17
133	Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes. <i>Cardiovascular Diabetology</i> , 2018, 17, 66.	6.8	36
134	p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. <i>Cardiovascular Diabetology</i> , 2018, 17, 16.	6.8	12
135	How to interpret the role of SDF-1 β on diabetic complications during therapy with DPP-4 inhibitors. <i>Cardiovascular Diabetology</i> , 2018, 17, 22.	6.8	6
136	Impaired cognitive processing speed in type 1 diabetic patients who had severe/recurrent hypoglycaemia. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1040-1045.	2.3	9
137	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 1-29.	0.1	0
138	Systemic and vascular inflammation in an in-vitro model of central obesity. <i>PLoS ONE</i> , 2018, 13, e0192824.	2.5	27
139	Diabetes and the Cardiovascular System. <i>Endocrinology</i> , 2018, , 131-159.	0.1	0
140	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications. <i>Diabetes Mellitus</i> , 2018, 21, 376-385.	1.9	0
141	DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2017, 16, 22.	6.8	13
142	Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 517-527.	1.8	5
143	A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 763-772.	3.1	14
144	Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: results from the OsMed HealthDB registry. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1416-1424.	4.4	18

#	ARTICLE	IF	CITATIONS
145	A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1348-1353.	2.3	34
146	Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2044-2050.	3.6	1
147	SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. <i>Diabetologia</i> , 2017, 60, 1385-1389.	6.3	186
148	Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (<i>Metab Syndr Relat Disord</i> 2017;15:269-275). <i>Metabolic Syndrome and Related Disorders</i> , 2017, 15, 266-268.	1.3	1
149	Mechanisms linking empagliflozin to cardiovascular and renal protection. <i>International Journal of Cardiology</i> , 2017, 241, 450-456.	1.7	36
150	Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 952-957.	2.3	5
151	The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 627-634.	3.3	5
152	Influence of health locus of control and fear of hypoglycaemia on glycaemic control and treatment satisfaction in people with Type 1 diabetes on insulin pump therapy. <i>Diabetic Medicine</i> , 2017, 34, 691-697.	2.3	19
153	Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. <i>Atherosclerosis</i> , 2017, 261, 117-123.	0.8	4
154	Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. <i>Atherosclerosis</i> , 2017, 266, 95-102.	0.8	42
155	miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. <i>Cardiovascular Research</i> , 2017, 113, 1627-1638.	3.8	62
156	Rationale and design of the DARWIN-T2D (Dapagliflozin Real World Evidence in Type 2 Diabetes). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1089-1097.	2.6	26
157	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	11.4	231
158	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 680-681.	11.4	113
159	Cognitive, neurophysiologic and metabolic sequelae of previous hypoglycemic coma revealed by hyperinsulinemic-hypoglycemic clamp in type 1 diabetic patients. <i>Metabolic Brain Disease</i> , 2017, 32, 1543-1551.	2.9	3
160	Comparison of lower limb muscle strength between diabetic neuropathic and healthy subjects using OpenSim. <i>Gait and Posture</i> , 2017, 58, 194-200.	1.4	21
161	Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3674-3682.	3.6	22
162	Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. <i>Cardiovascular Diabetology</i> , 2017, 16, 42.	6.8	80

#	ARTICLE	IF	CITATIONS
163	Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+CD133+ Stem Cells in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 125-131.	8.6	79
164	The <i>rs2274911</i> polymorphism in <i>GPRC6A</i> gene is associated with insulin resistance in normal weight and obese subjects. <i>Clinical Endocrinology</i> , 2017, 86, 185-191.	2.4	28
165	Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 6-month randomized crossover trial. <i>Diabetic Medicine</i> , 2017, 34, 262-271.	2.3	33
166	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. <i>Cardiovascular Diabetology</i> , 2017, 16, 118.	6.8	55
167	Randomized Summer Camp Crossover Trial in 5- to 9-Year-Old Children: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. <i>Diabetes Care</i> , 2016, 39, 1180-1185.	8.6	79
168	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. <i>Diabetes Care</i> , 2016, 39, 1151-1160.	8.6	98
169	Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and Death. <i>Circulation Research</i> , 2016, 118, 1930-1939.	4.5	97
170	Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry. <i>Atherosclerosis</i> , 2016, 251, 373-380.	0.8	10
171	Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. <i>Cardiovascular Diabetology</i> , 2016, 15, 111.	6.8	44
172	Altered EMG patterns in diabetic neuropathic and not neuropathic patients during step ascending and descending. <i>Journal of Electromyography and Kinesiology</i> , 2016, 31, 32-39.	1.7	13
173	Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures. <i>Diabetes Therapy</i> , 2016, 7, 679-693.	2.5	13
174	Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1112-1119.	2.6	25
175	Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 1391-1399.	3.3	83
176	Hypovitaminosis D is associated with erectile dysfunction in type 2 diabetes. <i>Endocrine</i> , 2016, 53, 831-838.	2.3	19
177	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 85-102.	2.6	9
178	Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 748-756.	3.6	65
179	Blood expression of matrix metalloproteinases 8 and 9 and of their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated diabetes mellitus. <i>Clinica Chimica Acta</i> , 2016, 456, 24-30.	1.1	15
180	A perspective on NETosis in diabetes and cardiometabolic disorders. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1-8.	2.6	45

#	ARTICLE	IF	CITATIONS
181	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 235-255.	3.3	30
182	NETosis Delays Diabetic Wound Healing in Mice and Humans. <i>Diabetes</i> , 2016, 65, 1061-1071.	0.6	233
183	GAIT ANALYSIS DRIVEN 2D FINITE ELEMENT MODEL OF THE NEUROPATHIC HINDFOOT. <i>Journal of Mechanics in Medicine and Biology</i> , 2016, 16, 1650012.	0.7	1
184	Hypovitaminosis D is associated with lower urinary tract symptoms and benign prostate hyperplasia in type 2 diabetes. <i>Andrology</i> , 2015, 3, 1062-1067.	3.5	12
185	Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. <i>Vascular Pharmacology</i> , 2015, 67-69, 21-29.	2.1	14
186	Circulating Stem Cells Associate With Adiposity and Future Metabolic Deterioration in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4570-4578.	3.6	18
187	Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. <i>Diabetologia</i> , 2015, 58, 2653-2662.	6.3	33
188	Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 136-145.	4.1	265
189	Alternative Activation of Human Macrophages Is Rescued by Estrogen Treatment In Vitro and Impaired by Menopausal Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E50-E58.	3.6	89
190	Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 107-115.	4.4	32
191	Hypoglycemia affects the changes in endothelial progenitor cell levels during insulin therapy in type 2 diabetic patients. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 733-738.	3.3	12
192	Direct effects of DPP-4 inhibition on the vasculature. Reconciling basic evidence with lack of clinical evidence. <i>Vascular Pharmacology</i> , 2015, 73, 1-3.	2.1	17
193	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015, 36, 2454-2462.	2.2	94
194	Diabetes modifies the relationships among carotid plaque calcification, composition and inflammation. <i>Atherosclerosis</i> , 2015, 241, 533-538.	0.8	11
195	High Temporal Resolution Detection of Patient-Specific Glucose Uptake from Human ex Vivo Adipose Tissue On-Chip. <i>Analytical Chemistry</i> , 2015, 87, 6535-6543.	6.5	26
196	Bone Marrow Macrophages Contribute to Diabetic Stem Cell Mobilopathy by Producing Oncostatin M. <i>Diabetes</i> , 2015, 64, 2957-2968.	0.6	85
197	Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 686-693.	2.6	71
198	Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. <i>Diabetes</i> , 2015, 64, 2969-2977.	0.6	50

#	ARTICLE	IF	CITATIONS
199	NAD+-dependent SIRT1 deactivation has a key role on ischemia-induced reperfusion-induced apoptosis. <i>Vascular Pharmacology</i> , 2015, 70, 35-44.	2.1	48
200	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 939-947.	11.4	189
201	Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 1357-1363.	3.3	7
202	Circulating Progenitor Cell Count Predicts Microvascular Outcomes in Type 2 Diabetic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2666-2672.	3.6	85
203	Carotid Plaque Calcification Predicts Future Cardiovascular Events in Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1937-1944.	8.6	43
204	p66Shc deletion or deficiency protects from obesity but not metabolic dysfunction in mice and humans. <i>Diabetologia</i> , 2015, 58, 2352-2360.	6.3	29
205	Effects of Age, Diabetes, and Vascular Disease on Growth Differentiation Factor 11: First-in-Human Study. <i>Diabetes Care</i> , 2015, 38, e118-e119.	8.6	12
206	NETosis is induced by high glucose and associated with type 2 diabetes. <i>Acta Diabetologica</i> , 2015, 52, 497-503.	2.5	188
207	Mechanisms of ectopic calcification: implications for diabetic vasculopathy. <i>Cardiovascular Diagnosis and Therapy</i> , 2015, 5, 343-52.	1.7	25
208	Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection. <i>Current Pharmaceutical Design</i> , 2014, 20, 2387-2394.	1.9	38
209	Sirtuin 1 stabilization by HuR represses TNF- α - and glucose-induced E-selectin release and endothelial cell adhesiveness <i>in vitro</i> : relevance to human metabolic syndrome. <i>Clinical Science</i> , 2014, 127, 449-461.	4.3	35
210	Endothelial Progenitor Cells Are Reduced in Acromegalic Patients and Can Be Restored by Treatment With Somatostatin Analogs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E2549-E2556.	3.6	8
211	Ectopic calcification in diabetic vascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 595-609.	3.4	13
212	Diabetes Causes Bone Marrow Autonomic Neuropathy and Impairs Stem Cell Mobilization via Dysregulated p66Shc and Sirt1. <i>Diabetes</i> , 2014, 63, 1353-1365.	0.6	131
213	Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis. <i>Atherosclerosis</i> , 2014, 237, 805-808.	0.8	76
214	3D finite element model of the diabetic neuropathic foot: A gait analysis driven approach. <i>Journal of Biomechanics</i> , 2014, 47, 3064-3071.	2.1	41
215	The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications. <i>Diabetes Care</i> , 2014, 37, 2884-2894.	8.6	138
216	Identification of diabetic neuropathic patients at risk of foot ulceration through finite element models and cluster analysis. <i>Journal of Foot and Ankle Research</i> , 2014, 7, .	1.9	1

#	ARTICLE	IF	CITATIONS
217	Biomechanical evaluation of diabetic foot through hierarchical cluster analysis. <i>Journal of Foot and Ankle Research</i> , 2014, 7, .	1.9	0
218	2â€Dimensional foot FE models for clinical application in gait analysis. <i>Journal of Foot and Ankle Research</i> , 2014, 7, .	1.9	0
219	Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy. <i>Current Diabetes Reports</i> , 2014, 14, 483.	4.2	26
220	The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients. <i>Cardiovascular Diabetology</i> , 2014, 13, 92.	6.8	25
221	Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients. <i>Atherosclerosis</i> , 2014, 235, 415-417.	0.8	18
222	Restoring stem cell mobilization to promote vascular repair in diabetes. <i>Vascular Pharmacology</i> , 2013, 58, 253-258.	2.1	24
223	An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. <i>Diabetologia</i> , 2013, 56, 1856-1866.	6.3	119
224	Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. <i>Acta Diabetologica</i> , 2013, 50, 943-949.	2.5	46
225	Myeloid calcifying cells promote atherosclerotic calcification via paracrine activity and allograft inflammatory factor-1 overexpression. <i>Basic Research in Cardiology</i> , 2013, 108, 368.	5.9	28
226	Achieving glycemic control in patients with type 2 diabetes and renal impairment. <i>Acta Diabetologica</i> , 2013, 50, 283-291.	2.5	23
227	The Endothelium Abridges Insulin Resistance to Premature Aging. <i>Journal of the American Heart Association</i> , 2013, 2, e000262.	3.7	26
228	The role of foot morphology on foot function in diabetic subjects with or without neuropathy. <i>Gait and Posture</i> , 2013, 37, 603-610.	1.4	38
229	Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans. <i>Diabetes Care</i> , 2013, 36, 943-949.	8.6	151
230	The limited clinical value of a specific diabetic cardiomyopathy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 599-605.	2.6	3
231	Stem cell compartmentalization in diabetes and high cardiovascular risk reveals the role of DPP-4 in diabetic stem cell mobilopathy. <i>Basic Research in Cardiology</i> , 2013, 108, 313.	5.9	63
232	Diabetes impairs mobilization of stem cells for the treatment of cardiovascular disease. <i>International Journal of Cardiology</i> , 2013, 168, 892-897.	1.7	42
233	Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond. <i>Atherosclerosis</i> , 2013, 229, 23-29.	0.8	48
234	Non-glycemic effects of pioglitazone and incretin-based therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 739-742.	3.4	10

#	ARTICLE	IF	CITATIONS
235	Circulating myeloid calcifying cells have antiangiogenic activity <i>via</i> thrombospondin-1 overexpression. <i>FASEB Journal</i> , 2013, 27, 4355-4365.	0.5	23
236	It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	41
237	Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-7.	3.8	42
238	Elevated white blood cell count is associated with prevalence and development of the metabolic syndrome and its components in the general population. <i>Acta Diabetologica</i> , 2012, 49, 445-451.	2.5	36
239	Abnormal muscle activation during gait in diabetes patients with and without neuropathy. <i>Gait and Posture</i> , 2012, 35, 101-105.	1.4	101
240	Integrated kinematics-kinetics-plantar pressure data analysis: A useful tool for characterizing diabetic foot biomechanics. <i>Gait and Posture</i> , 2012, 36, 20-26.	1.4	76
241	Endothelial progenitor cells in diabetes mellitus. <i>BioFactors</i> , 2012, 38, 194-202.	5.4	73
242	Treating diabetes today with gliclazide MR: a matter of numbers. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 14-19.	4.4	22
243	The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 518-522.	4.4	49
244	Which is the eligible patient to be treated with pioglitazone? The expert view. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 781-787.	3.3	1
245	Endothelial Dysfunction in Diabetes. <i>Diabetes Care</i> , 2011, 34, S285-S290.	8.6	381
246	Impaired endothelial progenitor cell recruitment may contribute to heart transplant microvasculopathy. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 70-76.	0.6	14
247	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 718-725.	4.4	50
248	At the crossroads of longevity and metabolism: the metabolic syndrome and lifespan determinant pathways. <i>Aging Cell</i> , 2011, 10, 10-17.	6.7	88
249	Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (<i>Journal of Diabetes and Its Complications</i> 24 [2010] 79-83). <i>Journal of Diabetes and Its Complications</i> , 2011, 25, 352-353.	2.3	4
250	Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. <i>Vascular Pharmacology</i> , 2011, 55, 10-16.	2.1	189
251	Defective recruitment, survival and proliferation of bone marrow-derived progenitor cells at sites of delayed diabetic wound healing in mice. <i>Diabetologia</i> , 2011, 54, 945-953.	6.3	70
252	PS12 - 62. Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011, 9, 133-133.	0.0	0

#	ARTICLE	IF	CITATIONS
253	Widespread Increase in Myeloid Calcifying Cells Contributes to Ectopic Vascular Calcification in Type 2 Diabetes. <i>Circulation Research</i> , 2011, 108, 1112-1121.	4.5	109
254	Insulin signaling and life span. <i>Pflugers Archiv European Journal of Physiology</i> , 2010, 459, 301-314.	2.8	56
255	Insulin sensitivity and secretion in young, healthy subjects are not changed by Zone and Mediterranean diets. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010, 3, 233-237.	0.5	2
256	Improved Function of Circulating Angiogenic Cells Is Evident in Type 1 Diabetic Islet-Transplanted Patients. <i>American Journal of Transplantation</i> , 2010, 10, 2690-2700.	4.7	22
257	Potential manipulation of endothelial progenitor cells in diabetes and its complications. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 570-583.	4.4	76
258	Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms. <i>Diabetes</i> , 2010, 59, 1006-1015.	0.6	268
259	The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1607-1609.	8.6	299
260	The Redox Enzyme p66Shc Contributes to Diabetes and Ischemia-Induced Delay in Cutaneous Wound Healing. <i>Diabetes</i> , 2010, 59, 2306-2314.	0.6	83
261	Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1097-1102.	8.6	168
262	Cell-based methods for ex vivo evaluation of human endothelial biology. <i>Cardiovascular Research</i> , 2010, 87, 12-21.	3.8	52
263	Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy. <i>Diabetes</i> , 2010, 59, 2152-2159.	0.6	139
264	Two Cases of Statin-Induced Rhabdomyolysis Associated with Mononeuropathy. <i>Clinical Drug Investigation</i> , 2010, 30, 347-350.	2.2	8
265	Rosuvastatin stimulates clonogenic potential and anti-inflammatory properties of endothelial progenitor cells. <i>Cell Biology International</i> , 2010, 34, 709-715.	3.0	23
266	Microangiopathy is independently associated with presence, severity and composition of carotid atherosclerosis in type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 21, 286-93.	2.6	34
267	Reduced endothelial progenitor cells and brachial artery flow-mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary open-angle glaucoma. <i>Acta Ophthalmologica</i> , 2010, 88, 135-141.	1.1	56
268	Autologous stem cell therapy for peripheral arterial disease. <i>Atherosclerosis</i> , 2010, 209, 10-17.	0.8	239
269	Exploring interactions among metabolic syndrome traits. Methods and meaning. <i>Atherosclerosis</i> , 2010, 210, 45-47.	0.8	2
270	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 37-47.	2.2	13

#	ARTICLE	IF	CITATIONS
271	Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis. PLoS ONE, 2010, 5, e11488.	2.5	84
272	Role of endothelial progenitor cells in diabetes mellitus. Expert Review of Endocrinology and Metabolism, 2009, 4, 575-589.	2.4	1
273	Critical confounders in the prognostic role of cellular biomarkers. Kidney International, 2009, 75, 755.	5.2	0
274	Characterizing multisegment foot kinematics during gait in diabetic foot patients. Journal of NeuroEngineering and Rehabilitation, 2009, 6, 37.	4.6	57
275	Diabetic gait and posture abnormalities: A biomechanical investigation through three dimensional gait analysis. Clinical Biomechanics, 2009, 24, 722-728.	1.2	138
276	Mechanisms and Significance of Progenitor Cell Reduction in the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2009, 7, 5-10.	1.3	18
277	Low CD34+ cell count and metabolic syndrome synergistically increase the risk of adverse outcomes. Atherosclerosis, 2009, 207, 213-219.	0.8	99
278	Effects of androgens on endothelial progenitor cells <i>in vitro</i> and <i>in vivo</i> . Clinical Science, 2009, 117, 355-364.	4.3	33
279	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	2.2	13
280	Oxidative stress and vascular disease in diabetes: Is the dichotomization of insulin signaling still valid?. Free Radical Biology and Medicine, 2008, 44, 1209-1215.	2.9	40
281	Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. Life Sciences, 2008, 82, 383-392.	4.3	23
282	The metabolic syndrome, diabetes and lung dysfunction. Diabetes and Metabolism, 2008, 34, 447-454.	2.9	73
283	Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2008, 82, S94-S101.	2.8	66
284	Technical notes on endothelial progenitor cells: Ways to escape from the knowledge plateau. Atherosclerosis, 2008, 197, 496-503.	0.8	233
285	Maternal Insulin Therapy Increases Fetal Endothelial Progenitor Cells During Diabetic Pregnancy. Diabetes Care, 2008, 31, 808-810.	8.6	13
286	Gender Differences in Endothelial Progenitor Cells and Cardiovascular Risk Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 997-1004.	2.4	162
287	Hypertension, Diabetes, Oxidative Stress, and Cardiovascular Remodeling: Making the Connection with p66shc. , 2008, , 279-291.		0
288	Rosiglitazone Reduces Glucose-Induced Oxidative Stress Mediated by NAD(P)H Oxidase via AMPK-Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2627-2633.	2.4	205

#	ARTICLE	IF	CITATIONS
289	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women. <i>Diabetes Care</i> , 2007, 30, 1241-1247.	8.6	144
290	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, 32-40.	2.6	16
291	Endothelial progenitor cells in the natural history of atherosclerosis. <i>Atherosclerosis</i> , 2007, 194, 46-54.	0.8	173
292	The good and the bad in the link between insulin resistance and vascular calcification. <i>Atherosclerosis</i> , 2007, 193, 241-244.	0.8	42
293	Significance of Endothelial Progenitor Cells in Subjects With Diabetes. <i>Diabetes Care</i> , 2007, 30, 1305-1313.	8.6	159
294	Acute effect of insulin on nitric oxide synthesis in humans: a precursor-product isotopic study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E776-E782.	3.5	19
295	Critical Assessment of Putative Endothelial Progenitor Phenotypes. <i>Experimental Hematology</i> , 2007, 35, 1479-1480.	0.4	15
296	Glucose tolerance is negatively associated with circulating progenitor cell levels. <i>Diabetologia</i> , 2007, 50, 2156-2163.	6.3	92
297	Endothelial dysfunction in type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, S39-S45.	2.6	98
298	Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. <i>Journal of Hypertension</i> , 2006, 24, 1115-1124.	0.5	122
299	Diabetes impairs progenitor cell mobilisation after hindlimb ischaemiaâ€“reperfusion injury in rats. <i>Diabetologia</i> , 2006, 49, 3075-3084.	6.3	250
300	Insulin generates free radicals in human fibroblasts ex vivo by a protein kinase C-dependent mechanism, which is inhibited by pravastatin. <i>Free Radical Biology and Medicine</i> , 2006, 41, 473-483.	2.9	23
301	Peripheral Blood CD34 + KDR + Endothelial Progenitor Cells Are Determinants of Subclinical Atherosclerosis in a Middle-Aged General Population. <i>Stroke</i> , 2006, 37, 2277-2282.	2.0	204
302	Pathophysiology of Circulating Progenitor Cells in Pulmonary Disease and Parallels with Cardiovascular Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 35, 403-404.	2.9	9
303	Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. <i>European Heart Journal</i> , 2006, 27, 2247-2255.	2.2	220
304	Endothelial progenitor cells and erectile dysfunction. <i>European Heart Journal</i> , 2006, 28, 639-640.	2.2	2
305	Insulin Signaling, Glucose Metabolism, and the Angiotensin II Signaling System: Studies in Bartter's/Citelman's syndromes. <i>Diabetes Care</i> , 2006, 29, 469-471.	8.6	25
306	Endothelial Progenitor Cells and the Diabetic Paradox. <i>Diabetes Care</i> , 2006, 29, 714-716.	8.6	87

#	ARTICLE	IF	CITATIONS
307	Number and Function of Endothelial Progenitor Cells as a Marker of Severity for Diabetic Vasculopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2140-2146.	2.4	393
308	Autologous Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells Improves Critical Limb Ischemia in Diabetes: Response to Huang et al.. <i>Diabetes Care</i> , 2006, 29, 478-479.	8.6	12
309	Insulin resistance: trigger or concomitant factor in the metabolic syndrome. <i>Panminerva Medica</i> , 2006, 48, 3-12.	0.8	11
310	Alcohol Consumption and Diabetes Mellitus. , 2005, , 501-510.		0
311	Diabetes Induces p66shcGene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1130-1136.	3.6	126
312	Endothelial Progenitor Cells and Vascular Biology in Diabetes Mellitus: Current Knowledge and Future Perspectives. <i>Current Diabetes Reviews</i> , 2005, 1, 41-58.	1.3	50
313	Metformin Prevents Glucose-Induced Protein Kinase C- β Activation in Human Umbilical Vein Endothelial Cells Through an Antioxidant Mechanism. <i>Diabetes</i> , 2005, 54, 1123-1131.	0.6	97
314	Postprandial Myocardial Perfusion in Healthy Subjects and in Type 2 Diabetic Patients. <i>Circulation</i> , 2005, 112, 179-184.	1.6	145
315	Arterio-venous gradient of endothelial progenitor cells across renal artery stenosis. <i>Atherosclerosis</i> , 2005, 182, 189-191.	0.8	13
316	Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1449-1457.	2.8	671
317	Characterization of endothelial progenitor cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1-2.	2.1	42
318	Mechanisms of endothelial dysfunction in obesity. <i>Clinica Chimica Acta</i> , 2005, 360, 9-26.	1.1	155
319	Endothelial Dysfunction in the Metabolic Syndrome. , 2005, , 321-338.		0
320	Acute Alcohol Consumption Improves Insulin Action Without Affecting Insulin Secretion in Type 2 Diabetic Subjects. <i>Diabetes Care</i> , 2004, 27, 1369-1374.	8.6	49
321	Insulin Generates Free Radicals by an NAD(P)H, Phosphatidylinositol 3'-Kinase-Dependent Mechanism in Human Skin Fibroblasts Ex Vivo. <i>Diabetes</i> , 2004, 53, 1344-1351.	0.6	79
322	Diabetic cardiomyopathy: A metabolic perspective. <i>American Journal of Cardiology</i> , 2004, 93, 13-16.	1.6	86
323	In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy. <i>Diabetologia</i> , 2003, 46, 524-530.	6.3	19
324	Elevated non-esterified fatty acids impair nitric oxide independent vasodilation, in humans: evidence for a role of inwardly rectifying potassium channels. <i>Atherosclerosis</i> , 2003, 169, 147-153.	0.8	24

#	ARTICLE	IF	CITATIONS
325	Moderate alcohol consumption, glucose metabolism and lipolysis: the effect on adiponectin and tumor necrosis factor $\hat{\pm}$. Journal of Endocrinological Investigation, 2003, 26, 1213-1218.	3.3	11
326	Nonesterified fatty acids and endothelial dysfunction. International Congress Series, 2003, 1253, 139-145.	0.2	2
327	L-Arginine-Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects: A Stable-Labelled ^{15}N Arginine Approach. Diabetes, 2003, 52, 795-802.	0.6	60
328	Monocyte NADPH Oxidase Subunit p22phox and Inducible Hemeoxygenase-1 Gene Expressions Are Increased in Type II Diabetic Patients: Relationship with Oxidative Stress. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1753-1759.	3.6	66
329	Visceral obesity is characterized by impaired nitric oxide-independent vasodilation. European Heart Journal, 2003, 24, 1210-1215.	2.2	60
330	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1233-1238.	3.6	33
331	Effects of Treatment With Sulfonylurea Drugs or Insulin on Ischemia-Induced Myocardial Dysfunction in Type 2 Diabetes. Diabetes, 2002, 51, 808-812.	0.6	89
332	Diabetic ketosis activates lymphomonocyte-inducible nitric oxide synthase. Diabetic Medicine, 2002, 19, 777-783.	2.3	12
333	Glucose Tolerance during Moderate Alcohol Intake: Insights on Insulin Action from Glucose/Lactate Dynamics. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1233-1238.	3.6	12
334	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. European Journal of Clinical Investigation, 2001, 31, 603-609.	3.4	70
335	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1301-1305.	3.6	16
336	Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1301-1305.	3.6	5
337	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 793-798.	3.6	64
338	Plasma Free Fatty Acids and Endothelium-Dependent Vasodilation: Effect of Chain-Length and Cyclooxygenase Inhibition. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 793-798.	3.6	43
339	Undermodeling affects minimal model indexes: insights from a two-compartment model. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E1171-E1193.	3.5	53
340	Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the role of nitric oxide. Diabetes, 1999, 48, 391-397.	0.6	22
341	Effect of different times of administration of a single ethanol dose on insulin action, insulin secretion and redox state. Diabetic Medicine, 1999, 16, 400-407.	2.3	13
342	Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes, 1999, 48, 1316-1322.	0.6	88

#	ARTICLE	IF	CITATIONS
343	Myocardial Dysfunction and Adrenergic Cardiac Innervation in Patients With Insulin-Dependent Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 1998, 31, 404-412.	2.8	118
344	Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1998, 274, E592-E599.	3.5	71
345	Forearm Nitric Oxide Balance, Vascular Relaxation, and Glucose Metabolism in NIDDM Patients. <i>Diabetes</i> , 1997, 46, 1040-1047.	0.6	91
346	Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. <i>Diabetes</i> , 1997, 46, 1040-1046.	0.6	35
347	Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals.. <i>Journal of Clinical Investigation</i> , 1996, 98, 108-115.	8.2	72
348	Epinephrine Exerts Opposite Effects on Peripheral Glucose Disposal and Glucose-Stimulated Insulin Secretion: A Stable Label Intravenous Glucose Tolerance Test Minimal Model Study. <i>Diabetes</i> , 1996, 45, 1373-1378.	0.6	38
349	Short-term diabetic ketosis alters n-6 polyunsaturated fatty acid content in plasma phospholipids.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 1650-1653.	3.6	21
350	Ethanol impairs insulin-mediated glucose uptake by an indirect mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2285-2290.	3.6	22
351	Alcohol Intake Impairs Glucose Counterregulation During Acute Insulin-Induced Hypoglycemia in IDDM Patients: Evidence for a Critical Role of Free Fatty Acids. <i>Diabetes</i> , 1993, 42, 1626-1634.	0.6	59
352	Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. <i>Diabetes</i> , 1993, 42, 1626-34.	0.6	9
353	Epinephrine's ketogenic effect in humans is mediated principally by lipolysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1992, 263, E250-E260.	3.5	5
354	Forearm ketone body metabolism in normal and in insulin-dependent diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1992, 263, E261-E267.	3.5	7
355	Effects of chronic alcohol intake on carbohydrate and lipid metabolism in subjects with type ii (non-insulin-dependent) diabetes. <i>American Journal of Medicine</i> , 1991, 90, 70-76.	1.5	56
356	Stable-Label Intravenous Glucose Tolerance Test Minimal Model. <i>Diabetes</i> , 1989, 38, 1048-1055.	0.6	89
357	Contribution of 3-hydroxyisobutyrate to the measurement of 3-hydroxybutyrate in human plasma: comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects.. <i>Journal of Lipid Research</i> , 1989, 30, 1811-1817.	4.2	29
358	Contribution of 3-hydroxyisobutyrate to the measurement of 3-hydroxybutyrate in human plasma: comparison of enzymatic and gas-liquid chromatography-mass spectrometry assays in normal and in diabetic subjects. <i>Journal of Lipid Research</i> , 1989, 30, 1811-7.	4.2	26
359	Type I Diabetes is Characterized by Insulin Resistance Not Only with Regard to Glucose, but also to Lipid and Aminoacid Metabolism*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 62, 1155-1162.	3.6	53
360	Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study. <i>Diabetes Therapy</i> , 0, , .	2.5	0